Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
Xenofon BaraliakosDésirée van der HeijdeJoachim SieperRobert D InmanHideto KamedaYihan LiXianwei BuAnna ShmagelPeter WungIn-Ho SongAtul DeodharPublished in: Arthritis research & therapy (2023)
NCT02049138.